To include your compound in the COVID-19 Resource Center, submit it here.

Nabi falls on NicVax miss

Nabi Biopharmaceuticals (NASDAQ:NABI) fell $3.74 (66%) to $1.89 on Monday after NicVax nicotine vaccine missed the primary endpoint in a Phase III

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE